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a  b  s  t  r  a  c  t
The  PRH/Hhex  transcription  factor  represses  multiple  genes  in  the  VEGF  signalling  pathway  (VSP)  to
inhibit  myeloid  cell  survival.  Protein  kinase  CK2  phosphorylates  PRH  and  counteracts  the inhibitory
effect  of this  protein  on cell  survival  by blocking  the  repression  of  VSP  genes.  Here  we  show  that  the
BCR-ABL/Src  kinase  inhibitor  dasatinib  decreases  PRH  phosphorylation  and  increases  PRH-dependent
repression  of  Vegf  and  Vegfr-1.  Moreover  in  the  absence  of  PRH,  dasatinib  does  not  inhibit  cell  survival
as  effectively  as  in  PRH  expressing  cells.  Thus  the  re-establishment  of  gene  control  by PRH is  in part
responsible  for  the  therapeutic  effects  of  dasatinib.
© 2012 Elsevier Ltd. 
1. Introduction
Protein kinase CK2 is a constitutive stress-responsive kinase that
promotes cell survival and is strongly implicated in tumourigene-
sis. CK2 activity is elevated in several cancer types including Acute
Myeloid Leukaemia (AML) and Chronic Myeloid Leukaemia (CML)
[1,2]. CML  cells express the oncogenic p210 BCR-ABL fusion pro-
tein, a constitutively active tyrosine kinase that stimulates multiple
growth promoting signalling pathways. BCR-ABL and Src family
kinases interact with each other and both have been shown to
increase CK2 activity [3,4]. The CML  therapeutic imatinib and its
derivative dasatinib inhibit the tyrosine kinase activity of BCR-ABL
resulting in leukaemic cell death. Dasatinib is a dual ABL-Src kinase
inhibitor that exhibits a more potent but less selective inhibition
of BCR-ABL than imatinib and is commonly used in treatment of
imatinib resistant CML. Although imatinib and dasatinib are well-
characterised treatments for CML  the downstream targets for their
action are not fully delineated.
The Proline-Rich Homeodomain (PRH/Hhex) protein regulates
many processes in embryonic development and in the adult
(reviewed [5]). In the haematopoietic system PRH is expressed in
myeloid lineages where it functions as a negative regulator of cell
growth. Loss of PRH function in myeloid cells contributes to the
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development of AML  subtypes [5].  PRH regulates myeloid survival
through the direct transcriptional repression of multiple genes
encoding components of the VEGF signalling pathway (VSP) includ-
ing Vegf, Vegfr-1, Vegfr-2, and neuropillin-1 [6,7]. Phosphorylation
of PRH by CK2 inhibits the DNA binding activity of this protein [7]
and CK2 antagonises PRH-dependent growth inhibition by altering
the stability and activity of PRH (manuscript in revision). Here we
show that an important effect of dasatinib is to decrease phospho-
rylation of PRH resulting in increased PRH repression activity at VSP
genes and decreased cell survival.
2. Materials and methods
Cell culture, quantitative PCR for Vegf and Vegfr-1 mRNA, PRH knockdown
with shRNA PRH or shRNA GFP (control) were performed as described previously
[6].  Western blotting was performed with mouse antibodies which preferentially
recognise hypophosphorylated PRH and rabbit antibodies that preferentially recog-
nise  pPRH [7]. Antibody for phosphoXRCC1 was a kind gift from Dr. Grant Stewart
(University of Birmingham). Antibody for pSrc was  a kind gift from Dr. Yotis Senis
(University of Birmingham). Antibody for pStat5 was obtained from New England
Biolabs.
3. Results
Inhibition of BCR-ABL results in the inhibition of CK2 activity in
BCR-ABL-dependent lymphoma cells [4].  K562 cells are a CML cell
line that express BCR-ABL and we hypothesised that the inhibition
of BCR-ABL in these cells might result in decreased CK2 activ-
ity leading to decreased phosphorylation of PRH and consequent
reduced cell survival. To test this we generated PRH knockdown
cells using shRNA for PRH or shRNA GFP as control (Fig. 1A) as
0145-2126 © 2012 Elsevier Ltd. 
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Fig. 1. Dasatinib reduces cell survival and decreases PRH phosphorylation. (A) Western blot with mouse polyclonal anti-PRH antibody showing PRH levels in cells selected
with  puromycin for 10 days following transfection with shRNAGFP (control) or shRNAPRH (PRH KD). Detection of Lamin A/C with laminA/C antibody is used as loading control
(B)  Control and PRH KD K562 cells were treated with dasatinib (0.5 M) for 8 h and an MTT assay was  then used to determine cell numbers. M + SD, n = 3. (C) K562 cells were
treated with dasatinib (30 M)  or imatinib (100 M)  for 6 h. The extacts were Western blotted for endogenous hypo-PRH or pPRH using mouse polyclonal PRH and rabbit
polyclonal phosphoPRH antibodies. The blot was stripped and reprobed for Lamin A/C as a control for protein loading and with a phospho-speciﬁc pXRCC1 antibody. (D)
Control and PRH KD K562 cells were treated with dasatinib (0.5 M)  for 6 h and then the extracts were probed with antibodies against phosphoSrc (pSrc), phosphoSTAT5
(pSTAT5), endogenous hypo-PRH, phospho-PRH or lamin A/C respectively. Control and knockdown cells treated with dasatinib both show inhibition of BCR-ABL signalling
and  Src signalling. Only control cells show the reduction in phosphoPRH levels with dasatinib treatment as the levels of pPRH in PRH KD cells is too low to detect.
described previously [6]. We  treated K562 shRNA control cells and
PRH knockdown (KD) cells with the BCR-ABL inhibitor dasatinib.
We used a high concentration of dasatinib to ensure that any effect
of PRH loss would be relevant to both the on-target effects of
this inhibitor (BCR-ABL/Src) and to any off-target effects on other
kinases. Importantly CK2 is not a direct target of dasatinib or ima-
tinib. As expected, dasatinib treatment brings about a signiﬁcant
reduction in cell number in control cells (Fig. 1B, 1 and 2) and PRH
KD results in increased cell number (Fig. 1B, 1 and 3, respectively).
This is because PRH KD is similar to the effect of increased phos-
phorylation of PRH by CK2. Importantly, treatment of the PRH KD
cells with dasatinib has no signiﬁcant effect on cell number (Fig. 1B,
4). We  conclude that PRH plays a signiﬁcant role in the ability of
dasatinib to inhibit K562 cell survival and that both the on-target
and any off-target effects of dasatinib treatment are in large part at
least dependent on the presence of PRH.
To conﬁrm that dasatinib treatment inhibits K562 cell survival
through PRH-mediated repression of VSP genes, we  looked at PRH
phosphorylation and VSP gene expression. Incubation of K562 cells
with high concentrations of dasatinib or imatinib for 6 h results
in a decrease in pPRH levels but has no effect on the amount of
total PRH (Fig. 1C). In the same experiment phosphorylation of an
unrelated CK2 target protein XRCC1 is also reduced conﬁrming that
CK2 is inhibited. Similar results were also obtained when cells were
treated with 0.5 M dasatinib for 6 h and extracts were blotted for
PRH and pPRH (Fig. 1D). To conﬁrm that this treatment blocks both
BCR-ABL activity and Src activity in control and knockdown cells
extracts were blotted for pSTAT5 as a down-stream marker of BCR-
ABL activity and pSrc. Fig. 1D shows that both BCR-ABL and Src
family kinases are strongly inhibited by dasatinib in control cells
and in PRH knockdown cells. As expected based on the reduction
in pPRH levels (Fig. 1B and 1D), dasatinib and imatinib decrease
expression of Vegfr-1 (Fig. 2 A, 2 and 3) and Vegf (Fig. 2B, 2 and
3). Furthermore, when there is little PRH, these drugs have little
or no effect on the expression of Vegfr-1 (Fig. 2A, 5 and 6) or Vegf
(Fig. 2B, 5 and 6). Finally, we  examined whether over-expression of
VEGF receptors and VEGF is able to counteract the inhibitory effects
of dasatinib on cell survival. The survival of cells over-expressing
VEGFR-1, VEGFR-2 and VEGF is not signiﬁcantly inhibited by dasa-
tinib whereas the survival of control cells is strongly inhibited
under the same conditions (Fig. 3 A). Fig. 3B shows that as expected
VEGF mRNA levels are indeed elevated in this experiment. This con-
ﬁrms that the effects of dasatinib on these cells are largely mediated
by the inhibition of VEGF gene expression.
4. Discussion
Blast crisis CML  cells have constitutively high BCR-ABL tyrosine
kinase activity, elevated VEGF levels that promote angiogenesis and
elevated CK2 activity. Imatinib and dasatinib inhibit the tyrosine
kinase activity of BCR-ABL and in the case of dasatinib also tar-
get other kinases such as the Src family tyrosine kinases, ckit and
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Fig. 2. Dasatinib represses VSP gene expression. (A) Control and PRH KD K562 cells were treated with dasatinib as above for 6 h prior to mRNA isolation and qPCR for Vegfr-1
mRNA.  M + SD, n = 3. (B) Vegf mRNA levels in the cells described in (A). M + SD, n = 3.
Fig. 3. (A) Cells with increased VSP gene expression are resistant to dasatinib treatment. Control and K562 cells over-expressing Vegfr-1, Vegfr-2 and Vegf were treated with
dasatinib (0.5 M)  for 8 h and an MTT  assay was  then used to calculate cell numbers. M + SD, n = 3. (B) mRNA obtained from cells treated as above was used for quantitative
PCR  to detect Vegf expression. (C) A model for the misregulation of PRH activity in CML. CK2 inhibits PRH and alleviates the repression of VSP genes resulting in increased
cell  survival. BCR-ABL increases CK2 activity leading to increased PRH phosphorylation, derepression of VSP genes and increased cell survival. Dasatinib treatment reduces
PRH  phosphorylation and re-establishes the repression of VSP genes leading to the inhibition of cell survival.
EphA2, resulting in cell death. Inhibition of these kinases leads to
the down-regulation of a variety of signalling pathways including
the PI3Kinase pathway and this results in decreased cell survival.
We have shown that dasatinb treatment brings about a reduction
in PRH phosphorylation. Signiﬁcantly, the inhibition of K562 cell
survival and the decrease in VSP gene expression brought about
by dasatinib treatment are largely dependent on the presence of
PRH (Fig. 3C). Although dasatinib inhibits multiple kinases, in the
absence of PRH even high concentrations of dasatinib have little
effect on cell survival. We  conclude that the re-establishment of
VSP gene regulation by PRH is responsible in large part for the
effects of these inhibitors on K562 cells. In agreement with this
conclusion de-regulated VSP gene expression is associated with
CML  [8].  We  infer that the elevation of CK2 activity by BCR-ABL
signalling [4] very likely results in elevated levels of PRH inacti-
vation in CML. Although CK2 is a pleiotropic kinase CK2 inhibitors
are being assessed for the treatment of BCR-ABL transformed ALL
and multiple AML  where CK2 activity has been found to be ele-
vated [1].  Our results suggest a molecular rationale for the use of
CK2 inhibitors in conjunction with BCR-ABL inhibitors in the treat-
ment of primary CML. Experiments in primary cells are required
to further investigate the importance of PRH phosphorylation and
determine whether the restoration of PRH activity through inhibi-
tion of CK2 may  be particularly of value in imatinib or dasatinib
resistant CML.
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